Cyclopharm Limited (ASX:CYC), Medical Developments International Limited (ASX:MVP) and Nova Eye Medical Limited (ASX:EYE) operate across different areas of medical technology. Cyclopharm supplies lung-imaging technology, Medical Developments produces acute-pain and respiratory products, while Nova Eye develops minimally invasive glaucoma-treatment devices.

Their latest financial results show three different stages of commercial development. Cyclopharm is increasing US Revenue while remaining loss-making, Medical Developments has returned to modest profitability and positive cash generation, while Nova Eye continues to expand sales and has moved toward positive EBITDA despite a relatively tight cash position.

2026 MedTech Context

Commercial-stage medical technology companies depend on more than regulatory approval. Hospital adoption, reimbursement, sales-force productivity and repeat product usage are important to turning approved products into sustainable revenue.

This is particularly relevant for smaller ASX healthcare companies, where commercial expansion needs to be balanced against available cash. Companies that demonstrate improving margins and cash generation can reduce reliance on repeated Equity funding as sales scale.

Cyclopharm Limited (ASX:CYC)

Company Profile

Cyclopharm develops and commercialises Technegas, a lung-ventilation imaging product used in nuclear medicine. The company sells the technology internationally and is expanding its presence in the United States following regulatory approval.

Its model combines installed equipment with recurring consumable demand, making growth in active hospital sites an important commercial driver.

Financial Performance

For the six months ended 30 June 2026, Cyclopharm reported record revenue of AUD 17.5 million.

US Technegas revenue reached AUD 2.1 million, while rest-of-world Technegas revenue was AUD 7.3 million. Third-party distribution contributed AUD 8.1 million.

Gross Margin was 56.3%.

The company remained loss-making, reporting a net loss of AUD 8.8 million for the half year.

Cash stood at AUD 12.2 million at 30 June 2026 after the company completed a AUD 13.5 million Capital raising during the period.

Outlook and Risks

Cyclopharm remains focused on increasing the number of revenue-generating US sites and converting contracted locations into active customers.

Growth in the installed base should support recurring consumable revenue, although the pace of hospital adoption remains difficult to control.

The company remains loss-making, making cash usage and progress toward Operating Leverage important through FY2027.

Medical Developments International Limited (ASX:MVP)

Company Profile

Medical Developments International produces Penthrox, an inhaled methoxyflurane analgesic used for acute pain management, alongside respiratory products including Breath-A-Tech.

Its products are sold across Australia and international markets through a combination of direct sales and distribution partners.

Penthrox remains the company's primary Earnings contributor.

FY2026 Financial Performance

For the year ended 30 June 2026, Medical Developments reported group revenue of AUD 42.6 million.

Net profit after tax was AUD 0.6 million, while EBIT was AUD 0.2 million.

Pain-management revenue reached approximately AUD 31.7 million and segment EBIT was AUD 9.4 million.

Respiratory revenue was AUD 10.9 million, with segment EBIT of approximately AUD 0.7 million.

Australian Penthrox revenue reached AUD 17.9 million, while European Demand also contributed to the year.

Operating cash flow was AUD 5.8 million and free cash flow reached AUD 4.2 million.

Medical Developments ended FY2026 debt-free with AUD 21.4 million of cash and deposits.

Outlook and Risks

Management expects Penthrox demand to remain the main growth driver during FY2027, including through a broader paediatric indication in selected international markets.

The respiratory division is expected to remain comparatively steady.

The main Business Risk is concentration around Penthrox, which generates the majority of earnings. International distribution and currency movements can also affect the timing and value of reported revenue.

Nova Eye Medical Limited (ASX:EYE)

Company Profile

Nova Eye Medical develops glaucoma-treatment devices, led by the iTrack Advance canaloplasty system.

The company sells directly into key markets including the United States and Germany and uses distributors across other territories.

Its strategy is centred on expanding minimally invasive glaucoma treatments and increasing the productivity of its commercial network.

FY2026 Financial Performance

Nova Eye reported FY2026 group sales of USD 23.7 million.

Sales excluding China were USD 22.7 million, while US sales reached USD 18.6 million. Germany contributed USD 2.0 million and other international markets generated USD 2.1 million.

The company achieved positive second-half EBITDA of USD 0.14 million, although full-year EBITDA remained a loss of USD 1.3 million.

Second-half gross margin reached 73%.

On an Australian-dollar statutory basis, FY2026 revenue was AUD 34.87 million and net loss after tax was AUD 4.33 million.

Cash at 30 June 2026 was AUD 0.96 million, while the company had approximately AUD 2.75 million of undrawn Debt facilities.

FY2027 Outlook

Nova Eye has guided to FY2027 sales excluding China of USD 26 million to USD 31 million.

Management is targeting positive EBITDA for the full year and expects existing resources to support the business under its current plan.

Continued improvement in US sales-force productivity will be important to meeting those objectives.

Risks

Liquidity remains the main financial consideration given the relatively low year-end cash balance.

The company also disclosed material uncertainty relating to going concern, although management expects improved trading and available facilities to support operations.

Performance remains heavily dependent on US sales, making reimbursement conditions and commercial execution important variables.

Risks to Watch

Cyclopharm remains exposed to the speed of US hospital adoption while operating at a loss.

Medical Developments is financially better positioned with positive Operating Cash Flow and no debt, although earnings remain concentrated in the Penthrox product family.

Nova Eye has produced improving revenue and EBITDA trends but carries the tightest Liquidity position of the three.

Outlook Through the Rest of 2026

Cyclopharm enters the next phase with AUD 17.5 million of first-half revenue and AUD 12.2 million of cash. Converting its US commercial pipeline into active revenue-generating sites remains the central priority.

Medical Developments enters FY2027 after reporting AUD 42.6 million of revenue, positive earnings and AUD 21.4 million of cash with no debt. Penthrox demand remains the main driver.

Nova Eye enters FY2027 after reporting USD 23.7 million of FY2026 sales and achieving positive EBITDA during the second half. The company is targeting continued sales growth and full-year positive EBITDA.

The three companies therefore enter FY2027 with different financial priorities: Cyclopharm is focused on scaling revenue and reducing losses, Medical Developments on building from a profitable and cash-generative base, and Nova Eye on converting sales growth into sustained positive earnings and cash generation.